Regulatory standard of this drug has been mentioned as monograph in the 6 th volume of Homoeopathic Pharmacopoeia of India, 1974. [49, 50] However, the evidence for successful treatment with Ocimum canum has remained anecdotal rather than experimental. Some leading Homoeopathic Materia Medicas [51] [52] [53] [54] [55] [56] [57] mention and some individual webpages [58] [59] [60] [61] claim its therapeutic utility, especially in urolithiasis, haematuria, renal colic accompanied by nausea and vomiting, coryza, spermatorrhoea and uric acid diathesis. The drug was standardized by the Central Council for Research in Homoeopathy (CCRH) at its Institutes/Units in Hyderabad, Ghaziabad, and Lucknow for pharmacognostic, physicochemical, and pharmacological aspects. [62] Later, drug proving was conducted by CCRH in double-blind, randomized, placebo-controlled design in 1996-1998 at Drug Proving Research Unit, Kolkata, and Homoeopathic Drug Research Institute, Lucknow, in 200C, 30C, and 12C potencies on 25 healthy human volunteers. [62, 63] Following that, clinical verification was carried out by the CCRH. [62] This paper presents the symptom compendium of Ocimum canum verified clinically during the Council's 2 nd phase verification studies in 2005-2010. 
materials and methods
The study was conducted at seven Institutes/Units of CCRH: Central Research Institute, Noida (Uttar Pradesh), Regional Research Institute, Puri (Odisha), Regional Research Institute, Shimla (Himachal Pradesh), Regional Research Institute, Kolkata, (West Bengal), Regional Research Institute, Imphal (Manipur), Clinical Research Unit, Port Blair (Andaman and Nicobar Islands), and Clinical Verification Unit, Vrindaban (Uttar Pradesh).
As per the inclusion criteria, the patients from all age groups, both sexes, having symptomatic similarity with Ocimum canum, and persons willing to participate were included in the study. If patient was taking any acute medicine, he/she was included in the study after a washout period of 1 week. Exclusion criteria were patients unwilling to participate, patients having a clinical presentation not corresponding with the study medicine, patients on regular medication for any systemic disease, and patients under chronic medicinal treatment. After providing patient information sheet in local vernaculars, informed written consent was obtained from the eligible subjects or the guardians in case of minors before participating in the study.
The study medicine was procured from one Good Manufacturing Practice compliant homoeopathic pharmacy in various potencies, namely, 6C, 30C, 200C, and 1M, and was distributed to above-mentioned institutes/units. First, the presenting signs and symptoms of the patients were recorded in case recording proforma. After that, the symptoms were repertorized using a repertory prepared for clinical verification by CCRH, and then, a specially developed Materia Medica was consulted for final selection of the remedy. Later, all these works were incorporated in one book published by CCRH. [63] If the presenting symptoms of the patient correspond with Ocimum canum, then the medicine was prescribed in 6C potency thrice a day till the improvement or aggravation occurred or for 5-7 days allowing the medicine to act. The medicine was dispensed by corresponding institute/unit pharmacy. In follow-up visits, the changes in signs and symptoms were noted. If there was any sign of improvement, then placebo was prescribed. If there was status quo, next higher potencies were prescribed in ascending order, 30C twice a day for 3-5 days in acute cases or for 5-7 days in chronic cases; 200C once a week were prescribed and were observed for 2 weeks. 1M potencies were advised once a fortnight, followed by 2 weeks observation. Keeping in mind the wide variation of presenting diseases or complaints, the timeline for follow-up was defined as 2 weeks or oftener a priori in the protocol. However, as each symptom has its own timeframe for recovery, provision had been kept to adjust the schedule as per individual's need and appropriateness of the cases. Dosage was decided as per the need of the case and in accordance with homoeopathic principles. Any potency could be tried for twice only. If adequate responses were not elicited, the cases were restudied and switched over to the next potency. If no change was observed even after the change of potencies also, then the case was closed and considered as a clinical failure or status quo. If the patient presented with new symptoms of mild intensity, placebo was prescribed; while the appearance of severe symptoms (new or aggravation of existing symptoms) Among the proving symptoms and clinical verification symptoms of CCRH, the following were most frequently observed symptoms: • "Dry cough; agg. morning, evening; amel. warm drinks, tea" (n = 54; prevalence 36.7% in the responding group, 95% CI: 29.1, 45.1) • "Sneezing with watery discharge; agg. cold; amel. warm drinks, tea" (n = 50; prevalence 34.0% in the responding group, 95% CI: 26.5, 42.3) • "Sore throat, itching, difficult deglutition; agg. cold;
amel. warm drinks, tea" (n = 34; prevalence 23.1% in the responding group, 95% CI: 16.8, 30.9) • "Headache with heaviness in forehead; agg. morning, bending forward; amel. lying down" (n = 24; prevalence 16.3% in the responding group, 95% CI: 10.9, 23.5).
with sufficient strength to cause considerable discomfort to the patient, called for a change of medicine or therapy and this case was considered as deteriorated one. "Clinical success" was defined a priori as cases showing clinical improvement, objective or subjective, of present complaint(s) as judged by the investigating physician(s) and/or as reported by the patient(s). "Clinical failures" were such cases showing "status quo" and/or worsening or deterioration of the condition, or cases requiring change of medicines. All the data were collected and compiled in specially designed Excel spreadsheet for analysis. Data were presented using descriptive statistics -mean, standard deviations (SDs), absolute values, percentages, and 95% confidence intervals (CIs). As per protocol, a minimum of two prescriptions for each symptom have been considered for pick-listing. Prevalence of the symptoms in the responding and nonresponding population was compared using Chi-square or Fisher's exact test, keeping P < 0.05 two-tailed as statistically significant.
results
A total of 214 patients were enrolled having similar "symptomatology" of Ocimum canum and meeting the prespecified eligibility criteria. Of these, 41 dropped out and 173 results per protocol were analyzed at the end of the study [ Figure 1 ]. Dropped out patients, as and when reported, were treated in the general out-patients of respective institutes/units. Table 2 ]. Among the 147 patients responding well to Ocimum canum, a total of 18 different types of clinical conditions or diagnoses were obtained; respiratory tract infection was the most frequent (n = 83; 56.46%) [ Table 3 ]. Contd...
Among the existing symptoms available from other literature, the most frequently observed symptom was "renal colic, especially right sided" (n = 5, prevalence 3.4% in the responding group, 95% CI: 1.3, 8.2). Symptom "scanty urine" did not show any improvement (n = 0, prevalence 0% in the responding group, 95% CI: 0, 3.2) [ Table 2 ].
Among new clinical symptoms, the most frequently observed symptoms were as follows:
• "Tongue clean" (n = 111, prevalence 75.5% in the responding group, 95% CI: 67.6, 82.1) • "Thermal relation -chilly" (n = 50, prevalence 34 Significantly, higher prevalence of the symptoms under question in the responding population than in the nonresponding population was found in case of 5 symptoms:
However, as far as the peculiarity of the symptoms is considered, the first three may be segregated further and may be deemed as the most promising symptoms for future research [ Table 4 ].
disCussion
A total of 22 symptoms of Ocimum canum were verified, of which 10 symptoms were from the compendium of proving, carried out previously by the Council and the rest 12 were clinical re-confirmation of symptoms from other literature. Besides, 42 new clinical symptoms were also identified. Most frequently encountered clinical conditions were respiratory tract infections, migraine, arthritis, renal stone, ureteric stone, and dermatitis.
At this point of time, likelihood ratios (LRs) seems to be the mainstay of future homoeopathic research for confirming the accuracy of the symptoms enlisted under any drug (i.e., drug and Materia Medica validation). [64, 65] Retrospective assessment of prevalence and LR of symptoms in good responders could be a mean for better selection of symptoms for prospective research; however, feasibility of conducting such retrospective investigations deserves further discussion. Although the presence and/or absence of Ocimum canum symptoms in the "medicine worked" population can be identified in retrospective way, still finding out the same in the remainder of the population treated during the period of study from the available CCRH database is not feasible. Hence, formation of the 2 × 2 contingency table of prognostic research and calculation of LR does not appear to be probable at this point of time. These symptoms with low prevalence need greater number of cases to establish substantial LR. All these results should be considered as provisory and need confirmation through prospective research of real prevalence in order to the knowledge of medicines and more importantly, to increase posterior chance of correct selection of medicine, improve prescription accuracy and clinical outcomes. [66] The causal association can be tested prospectively and systematically in all cases using modified Naranjo's criteria [67] in future studies.
The spheres of action of medicine identified were head, nose, respiratory tract, ear, genitourinary system, musculoskeletal system, and skin. A few mental symptoms were elicited -anxious; confused; desires company; desire to be alone; intelligent; mild, gentle; concentration difficult; forgetful, weak memory; dull; sad, gloomy, melancholic; irritable; malaise, lethargy. Moreover, our initial observation also elicited a few polar symptoms -both thermally chilly and hot; desire for and aversion to salty food, sour, and sweet; appetite increased and decreased; thirst increased and decreased; tongue clean and coated; tongue moist and dry; sweat scanty and profuse; desire company and desire to be alone; intelligent and dull. These opposite (polar) symptoms warrant further rigorous evaluation. [68] Apart from the above observations, during the study, a group of valuable symptoms also emerged reflecting the general characters of the drug and thereby widening the probable scope of its therapeutic applicability. The mental features obtained were sad, depressed, melancholic mood; forgetful and weak memory; irritability; and aversion to noise, light, and crowd. These may be considered as useful clinical concomitants, carrying much importance to prescribe the medicine. The overall results generated were contributed by different study sites, indicating enhanced generalizability of the study findings. However, being an observational trial, this study cannot address the threats to various internal validity issues; for example, absence of matching, randomization and blinding, the placebo effect, the therapeutic relationship with the clinician (empathy, compassion, social desirability, etc.), the regression effect toward the mean, and the use of undisclosed concomitant treatments, if any. The research protocol should have anticipated and kept provision to address the issues related to spontaneous recovery of the symptoms under question, for example, using modified Naranjo's criteria. However, this observational trial, being exploratory in nature, cannot evaluate the same. In addition, we compared between responding and nonresponding patients for one medicine. This way, we can only get some idea of symptoms that can be further investigated. These could be of great value when compared with similar data of other medicines. However, the prevalence of symptoms should preferably be compared with the whole population. If possible, this can be derived from literature or estimated. [66, 69] This symptom prevalence should necessarily be higher in the responding population than in the whole population to be considered as an indication for the given medicine. However, it depends on the cutoff value for this symptom, which can vary strongly. The prevalence of any symptom under investigation can probably be best assessed in multicenter drug validation or clinical verification programs that can produce more reliable and generalizable nation-wide data. Some data are already available, [66, 69] but still in a nascent state and how far they can be extrapolated to the remaining nations remains a matter subjected to future research.
ConClusions
This paper generated a list of clinically verified symptoms of Ocimum canum and warrants further evaluation using enhanced methodological rigor. On many occasions, a limited number of prescriptions were generated for specific symptoms making interpretation difficult. Calculation of LR will enable more accurate and quantitative description of strength of the probable or claimed characteristic symptoms of the drug, based on empirical evidence instead of assumption. Hence, further confirmation of the symptoms in larger sample size, analysis of polarity, and prospective estimation of LR of the symptoms using Bayesian statistical methods in routine practice is necessary before inclusion of the symptoms in Homoeopathic Materia Medica and Repertory.
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There are no conflicts of interest. referenCes Prevalencia de síntomas en una cohorte de 147 pacientes que mejoraron con el medicamento homeopático Ocimum canum: Estudio clínico, observacional, multicéntrico, abierto de verificación RESUMEN Contexto: La verificación clínica es un programa de investigación en curso del Council, en el que se han comprobado muchos medicamentos homeopáticos raros. Objetivos: Verificar clínicamente la "sintomatología" de Ocimum canum y establecer la prevalencia de los síntomas. Materiales y métodos: Se trataba de un estudio clínico, observacional, multicéntrico abierto. Se incluyó un total de 214 pacientes después comprobar la coincidencia de los síntomas disponibles, el compendio del medicamento y los criterios de elegibilidad de siete unidades/institutos del Council. El medicamento se prescribió en las potencias de 6C, 30C, 200C y 1M, en función de las necesidades de cada paciente, cumpliendo con los principios homeopáticos y el protocolo desarrollado por el Council. Los datos recogidos se presentaron con estadísticas descriptivas. La prevalencia de los síntomas en la población de respondedores y no respondedores se comparó con la prueba de chi cuadrado o la prueba exacta de Fisher. Resultados: Se analizó un total de 173 casos completos; la proporción de hombres / mujeres era de 76/79 y la edad media se situó en 31,09 años. Conforme a la valoración subjetiva de los médicos, se dieron 147 (85,0%) casos de "éxito clínico" y 26 (15,0%) "fracasos". Como regla general, se consideró un mínimo de dos prescripciones para el listado de cada síntoma. El número de síntomas verificados fue el siguiente: síntomas de patogenesias (n = 10), síntomas de otras bibliografías (n = 12) y observaciones clínicas nuevas (n = 42). Conclusiones: Se verificó un total de 22 síntomas y se identificaron 42 síntomas clínicos nuevos. Hay que tener en cuenta y evaluar los síntomas generales nuevos observados y los síntomas polares. Es esencial replicar estos estudios y estimar la relación de probabilidad en la práctica clínica general para la confirmación de los síntomas y su incorporación en la bibliografía homeopática. 
